While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

SynuSight Biotech ("SynuSight"), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics ("ABLi"), a biotechnology company ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

Could diabetes medications have an influence beyond simply regulating blood sugar? This question is gaining ground in laboratories, where it is being asked whether these treatments are also ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

There is an undeniable connection between a strong immune system and nutrition. Learn why what you eat matters and other ways to boost your immune system.